Mandatory Efficacy Trials: US FDA Affirms Broad Scope Of New Post-Market Authority
Executive Summary
Updated guidance on its authority to mandate postmarketing studies affirms that a new power to impose requirements to look for diminished efficacy reaches beyond the opioid drug class.